Concord Biotech Limited reported earnings results for the second quarter and six months ended September 30, 2024. For the second quarter, the company reported sales was INR 3,101.81 million compared to INR 2,623.46 million a year ago. Revenue was INR 3,202.07 million compared to INR 2,704.72 million a year ago. Net income was INR 957.41 million compared to INR 810.2 million a year ago. Basic earnings per share from continuing operations was INR 9.15 compared to INR 7.74 a year ago.
For the six months, sales was INR 5,259.83 million compared to INR 4,571.73 million a year ago. Revenue was INR 5,463.16 million compared to INR 4,719.54 million a year ago. Net income was INR 1,553.34 million compared to INR 1,355.14 million a year ago. Basic earnings per share from continuing operations was INR 14.85 compared to INR 12.95 a year ago.
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Companyâs offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
